alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis.
alpha-Synuclein exists in two different compartments in vivo-- correspondingly existing as two different forms: a membrane-bound form that is predominantly alpha-helical and a cytosolic form that is randomly structured. It has been suggested that these environmental and structural differences may play a role in aggregation propensity and development of pathological lesions observed in Parkinson's disease (PD). Such effects may be accentuated by mutations observed in familial PD kindreds. In order to test this hypothesis, wild-type and A53T mutant alpha-synuclein interactions with rat brain synaptosomal membranes were examined. Previous data has demonstrated that the A30P mutant has defective lipid binding and therefore was not examined in this study. Electron microscopy demonstrated that wild-type alpha-synuclein fibrillogenesis is accelerated in the presence of synaptosomal membranes whereas the A53T alpha-synuclein fibrillogenesis is inhibited under the same conditions. These results suggested that subtle sequence changes in alpha-synuclein could significantly alter interaction with membrane bilayers. Fluorescence and absorption spectroscopy using environment sensitive probes demonstrated variations in the inherent lipid properties in the presence and absence of alpha-synuclein. Addition of wild-type alpha-synuclein to synaptosomes did not significantly alter the membrane fluidity at either the fatty acyl chains or headgroup space, suggesting that synaptosomes have a high capacity for alpha-synuclein binding. In contrast, synaptosomal membrane fluidity was decreased by A53T alpha-synuclein binding with concomitant packing of the lipid headgroups. These results suggest that alterations in alpha-synuclein-lipid interactions may contribute to physiological changes detected in early onset PD.
Jo
Euijung
E
Centre for Research in Neurodegenerative Diseases, University of Toronto, Ontario, Canada.
Darabie
Audrey A
AA
Han
Kyung
K
Tandon
Anurag
A
Fraser
Paul E
PE
McLaurin
JoAnne
J
D000409:Alanine / Q000235:genetics / Q000378:metabolism; D000818:Animals; D002942:Circular Dichroism; D019281:Dimerization; D005227:Fatty Acids / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D008854:Microscopy, Electron; D009154:Mutation / Q000235:genetics; D009419:Nerve Tissue Proteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism* / Q000648:ultrastructure; D011485:Protein Binding; D020836:Protein Structure, Quaternary; D051381:Rats; D013050:Spectrometry, Fluorescence; D013499:Surface Properties; D013570:Synaptic Membranes / Q000378:metabolism* / Q000648:ultrastructure; D013574:Synaptosomes / Q000378:metabolism* / Q000648:ultrastructure; D051843:Synucleins; D014443:Tyrosine / Q000737:chemistry / Q000378:metabolism; D051844:alpha-Synuclein
D005227:Fatty Acids; D009419:Nerve Tissue Proteins; C497604:SNCA protein, human; C497606:Snca protein, rat; D051843:Synucleins; D051844:alpha-Synuclein; D014443:Tyrosine; D000409:Alanine